U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07153289) titled 'CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)' on Aug. 08.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages. Standard treatments, such as multi-agent chemotherapy, provide only marginal survival benefits and are often associated with significant toxicity. Novel approaches are urgently needed.
The ResCPa study is a first-in-human, multicenter, phase I/IIa investigator-initiated trial evaluating the safety, feasibility, and preliminary efficacy of autologous CD318-target...